La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Medivolve Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

David Preiner

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	3.3yrs
Proprietà del CEO	1.6%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	4.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di David Preiner rispetto agli utili di Medivolve?
Data	Compenso totale	Stipendio	Guadagni aziendali
Mar 31 2024	n/a	n/a	-CA$3m
Dec 31 2023	n/a	n/a	-CA$4m
Sep 30 2023	n/a	n/a	-CA$9m
Jun 30 2023	n/a	n/a	-CA$10m
Mar 31 2023	n/a	n/a	-CA$15m
Dec 31 2022	CA$4m	CA$260k	-CA$15m
Sep 30 2022	n/a	n/a	-CA$7m
Jun 30 2022	n/a	n/a	CA$2m
Mar 31 2022	n/a	n/a	CA$2m
Dec 31 2021	CA$1m	CA$146k	-CA$7m

Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di David sia ragionevole rispetto ad aziende di dimensioni simili nel mercato US.

Compensazione vs guadagni: La retribuzione di David è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

David Preiner

3.3yrs

Mandato

CA$4,059,393

Compensazione

Mr. David Preiner is Founder, President, CEO and Director of Exponential Genomics Inc. He studied at Harvard University (Ext. BLA candidate) - Biology, Engineering Sciences, Nanotechnology and has experien...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Michael McCarthy	Member of Advisory Board	4.3yrs	Nessun dato	Nessun dato
James Beeland Rogers	Member of Strategic Advisory Board	4.3yrs	Nessun dato	Nessun dato
Joseph Sugerman	Member of Advisory Board	4.3yrs	Nessun dato	Nessun dato
Glenn Copeland	Member of Advisory Board	no data	Nessun dato	Nessun dato
Richard Dolan	Member of Strategic Advisory Board	4.3yrs	Nessun dato	Nessun dato
Paulo Iglessias	Member of Advisory Board	4.3yrs	Nessun dato	Nessun dato
Mike Mancias	Member of Advisory Board	4.3yrs	Nessun dato	Nessun dato

4.3yrs

Durata media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di MEDV.F sono considerati esperti (durata media dell'incarico 4.3 anni).

Medivolve Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Medivolve Inc. Announces Resignation of Peter Michel as Chief Financial Officer

Medivolve Inc. Announces the Resignation of Wen Ye as Board of Director

Medivolve Inc. Announces the Resignation of Beverley Richardson from its Board of Directors

Medivolve Inc. Announces Chief Financial Officer Changes

Beverly Richardson Joins Questcap’s Board of Directors

Recent updates

Medivolve Inc. Announces Resignation of Peter Michel as Chief Financial Officer

Medivolve Inc. Announces the Resignation of Wen Ye as Board of Director

Medivolve Inc. Announces the Resignation of Beverley Richardson from its Board of Directors

Medivolve Inc. announced that it expects to receive CAD 4 million in funding

Medivolve Inc. announced that it has received CAD 1.2 million in funding

Medivolve Inc. Announces Chief Financial Officer Changes

Medivolve Inc. announced that it expects to receive CAD 2.6 million in funding

Medivolve Announces New COVID-19 Testing Mobile Vans Expanding On-Site Testing Opportunities to Schools, Workplaces, and Events

Medivolve Inc. announced that it has received CAD 12 million in funding

Medivolve Inc. (OTCPK:COPR.F) completed the acquisition of Electronic Health Platform of Myosin Inc.

Medivolve Inc. (OTCPK:COPR.F) signed a binding agreement to acquire Marbella Pharmacy for $0.5 million.

Medivolve Inc. and Marvel Diagnostics Inc. Complete First Stage Clinical Testing of BlowFISH

Medivolve Inc. Launches Business to Business Sales Initiatives

Medivolve Inc. (OTCPK:COPR.F) has signed a letter of intent to acquire Modern Rx LLC for $0.35 million.

Medivolve Inc. Announces the Launch of an Operating Model with Besser Brands in the State of Florida

Medivolve Inc. (NEOE:MEDV) signed a binding letter of intent to acquire Karland Health, LLC.

Medivolve Inc Collection Sites Provides Update with January Sales of 73,973 Tests At an Average Price of $96 Per Test

Medivolve Inc. (NEOE:MEDV) entered into an agreement to acquire Noble Bioscience Corp.

Medivolve Inc. (NEOE:MEDV) entered into a share purchase agreement to acquire a 13.2% stake in Marvel Diagnostics Inc. for $0.33 million.

Medivolve Inc. announced that it has received CAD 5 million in funding

Beverly Richardson Joins Questcap’s Board of Directors

QuestCap Provides COVID-19 Testing Kits to Kinross Gold’s Russian Operations

QuestCap Inc. announced that it expects to receive CAD 5 million in funding

QuestCap Inc. Sign Fifteen Lease Agreements Between Collection Sites, Llc and Orange County, and H&S Energy, Llc to Begin the Roll Out Network of Pop-Up Covid-19 Testing Sites

QuestCap Inc. (CNSX:QSC) completed the acquisition of Collection Sites, LLC.

QuestCap Inc. (CNSX:QSC) entered into a binding letter of intent to acquire Collection Sites, LLC for CAD 2.8 million.

QuestCap Inc. (CNSX:QSC) entered into arm's length agreement to acquire 40% stake in Spectral Analytics, Inc. for $2 million.

QuestCap Inc. (CNSX:QSC) acquired 40% issued and outstanding shares in Amino Therapeutics, Inc.

QuestCap Inc. (CNSX:QSC) completed the acquisition of 49% stake in Athletics and Health Solutions Inc.

QuestCap Inc. (CNSX:QSC) entered into a binding letter of agreement to acquire 28% stake in Sanaty IPS S.A.S. from Latin-Canada Pharma Inc. for CAD 2.7 million.